NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Amicus Therapeutics Inc (NASDAQ: FOLD)

 
FOLD Technical Analysis
5
As on 9th Jul 2025 FOLD SHARE Price closed @ 6.42 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 11.00 & Strong Sell for SHORT-TERM with Stoploss of 12.54 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

FOLDSHARE Price

Open 6.28 Change Price %
High 6.45 1 Day 0.20 3.22
Low 6.27 1 Week 0.49 8.26
Close 6.42 1 Month 0.20 3.22
Volume 5592548 1 Year -5.61 -46.63
52 Week High 14.00 | 52 Week Low 5.64
 
NASDAQ USA Most Active Stocks
NCNA 0.06 0.00%
AMRS 0.14 100.00%
PLUG 1.78 25.35%
NVDA 162.88 1.80%
EVOK 6.99 162.78%
HCTI 0.02 0.00%
LCID 2.28 -0.87%
TLRY 0.68 15.25%
LMDX 0.02 0.00%
AQMS 0.58 20.83%
 
NASDAQ USA Top Gainers Stocks
KTRA 6.30 2763.64%
IDRA 8.64 1909.30%
REDU 3.41 1075.86%
CTXRW 0.14 600.00%
TBIO 0.30 500.00%
NBSTU 12.99 220.74%
NDRAW 0.03 200.00%
EVOK 6.99 162.78%
HCVIU 9.00 159.37%
GLSPT 33.43 138.62%
 
NASDAQ USA Top Losers Stocks
OTIC 0.01 -91.67%
PTRAW 0.23 -89.59%
ACAQ-UN 2.50 -73.49%
AGBA 0.35 -71.31%
AXAS 0.03 -70.00%
BPTH 0.21 -66.67%
AXDX 0.03 -66.67%
TFFP 0.06 -62.50%
HEPA 0.12 -62.50%
MILEW 0.06 -53.85%
 
 
FOLD
Daily Charts
FOLD
Intraday Charts
Whats New @
Bazaartrend
FOLD
Free Analysis
 
FOLD Important Levels Intraday
RESISTANCE6.77
RESISTANCE6.66
RESISTANCE6.59
RESISTANCE6.52
SUPPORT6.32
SUPPORT6.25
SUPPORT6.18
SUPPORT6.07
 
FOLD Forecast July 2025
4th UP Forecast10.99
3rd UP Forecast9.52
2nd UP Forecast8.62
1st UP Forecast7.71
1st DOWN Forecast5.13
2nd DOWN Forecast4.22
3rd DOWN Forecast3.32
4th DOWN Forecast1.85
 
FOLD Weekly Forecast
4th UP Forecast8.06
3rd UP Forecast7.53
2nd UP Forecast7.21
1st UP Forecast6.88
1st DOWN Forecast5.96
2nd DOWN Forecast5.63
3rd DOWN Forecast5.31
4th DOWN Forecast4.78
 
FOLD Forecast2025
4th UP Forecast22.84
3rd UP Forecast17.57
2nd UP Forecast14.32
1st UP Forecast11.06
1st DOWN Forecast1.78
2nd DOWN Forecast-1.48
3rd DOWN Forecast-4.73
4th DOWN Forecast-10
 
 
FOLD Other Details
Segment EQ
Market Capital 2830569472.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
FOLD Address
FOLD
 
FOLD Latest News
 
Your Comments and Response on Amicus Therapeutics Inc
 
FOLD Business Profile
Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania. Address: 3675 Market Street, Philadelphia, PA, United States, 19104
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service